financetom
Business
financetom
/
Business
/
Fitch Ratings revises OYO's outlook to positive; affirms ratings at 'B-'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Fitch Ratings revises OYO's outlook to positive; affirms ratings at 'B-'
May 31, 2023 8:20 AM

Fitch Ratings on Wednesday, May 31, revised the outlook on India-based Oravel Stays Ltd — which operates travel tech firm and brand OYO — for long-term foreign and local-currency issuer default ratings to positive from stable, while affirming the ratings at 'B-'.

Share Market Live

NSE

The rating agency also affirmed the rating on the $660-million senior secured term loan facility due 2026, issued by OYO's fully-owned subsidiary, Oravel Stays Singapore Pte Ltd, at 'B-'.

"The outlook revision reflects our view that OYO is on track to generate positive EBITDA and cash flow from operations (CFO) sustainably. This follows positive EBITDA in every quarter of the financial year ended March 2023 (FY23), which is the first year of profits since OYO's incorporation in 2012," according to a statement by the agency.

Further, Fitch expects significant growth in the company's EBITDA in FY24, led by an ongoing demand recovery in the travel and tourism industry, the company's stable gross margins, and a reduction in operating costs.

The rating reflects OYO's asset-light business model "that benefits from minimal capex needs, largely exclusive distribution rights, pricing control over storefront inventory, fixed revenue share and strong long-term growth potential," it added.

"The business profile's strengths are mitigated by the sector's high competitive intensity and demand cyclicality. The rating also reflects OYO's adequate liquidity," Fitch said.

The ongoing demand recovery in the industry is expected to drive revenue growth of over 20 percent, it said, adding, "We also expect OYO's operating leverage to benefit from a sustained reduction in costs and drive high single-digit EBITDA margins in FY24."

On improved cost structure, Fitch said, "We expect the cost reduction measures OYO undertook in recent years to support its improving profitability in FY24. We believe such reductions will not affect growth, as it has increased its business development staff to prioritise storefront additions."

The agency said it estimates that "OYO's unrestricted cash at FYE23 is sufficient to fund its Fitch-estimated free cash flow deficit of around $7 million and annual debt repayment of around $6 million in FY24".

However, it said, "A greater cash burn than we expect could weaken OYO's liquidity. Any potential default of the debt outstanding at one of OYO's shareholding entities owned by the founder may be a reputational risk and affect OYO's operations, and we treat this as an event risk."

(Edited by : Shoma Bhattacharjee)

First Published:May 31, 2023 5:20 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
WeRide GXR Robotaxi Gets Approval for Fully Unmanned Commercial Operations in Beijing
WeRide GXR Robotaxi Gets Approval for Fully Unmanned Commercial Operations in Beijing
Feb 24, 2025
07:51 AM EST, 02/24/2025 (MT Newswires) -- WeRide ( WRD ) said Monday it received approval to launch its latest robotaxi model, the GXR, for fully unmanned paid raid-hailing services in Beijing, China. The new model's service area covers key regions within the Beijing Economic-Technological Development Area. It is also approved for operation on highways, the company said. WeRide (...
XORTX Starts Gout Program New Drug Application Talks With FDA
XORTX Starts Gout Program New Drug Application Talks With FDA
Feb 24, 2025
07:55 AM EST, 02/24/2025 (MT Newswires) -- Xortx Therapeutics ( XRTX ) on Monday said it has submitted a Type C meeting request with the U.S. Food and Drug Administration for its XRx-026 program to treat gout. The meeting is expected to be held within 75 days of the FDA's receipt of the request. The XRx-026 program is developing Xorlo...
Beyond Completes Buy Buy Baby Brand Acquisition
Beyond Completes Buy Buy Baby Brand Acquisition
Feb 24, 2025
07:53 AM EST, 02/24/2025 (MT Newswires) -- Beyond (BYON) said Monday it has closed the $5 million acquisition of the Buy Buy Baby brand from BBBY Acquisition Co. The deal includes intellectual property, databases, vendor relationships, and other content pertaining to the brand, the company said. Beyond shares were up over 2% in recent Monday premarket activity. ...
Market Chatter: Apollo Buying Bridge Investment Group for $1.5 Billion in Stock
Market Chatter: Apollo Buying Bridge Investment Group for $1.5 Billion in Stock
Feb 24, 2025
07:55 AM EST, 02/24/2025 (MT Newswires) -- Apollo Global Management ( APO ) is buying real-estate investment firm Bridge Investment Group ( BRDG ) for roughly $1.5 billion in stock, The Wall Street Journal reported Monday, citing people familiar with the matter. Bridge Executive Chairman Bob Morse will join Apollo as partner and head of its real-estate equity business, according...
Copyright 2023-2026 - www.financetom.com All Rights Reserved